Trial Profile
Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Interstitial lung diseases; Pneumonitis; Severe acute respiratory syndrome
- Focus Therapeutic Use
- 02 Apr 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 02 Apr 2020 Planned primary completion date changed from 1 Apr 2020 to 9 Apr 2020.
- 23 Mar 2020 New trial record